The United States Food and Drug Administration officially approved the use of a single-dose vaccine of Johnson & Johnson On Saturday, paving the way for weapons shots, Johnson & Johnson is 85% successful against the corona virus disease COVID-19, hospitalization and death, based on evidence from a three continent sample. Even where the South African version is expanding, this shot maintained its security.
Health authorities who want to step up vaccine in a coronavirus race and its worrying variations have looked forward to the one-and-done inoculation.
Biden: Don’t let the hell go
In a speech on Saturday afternoon President Joe Biden commended the exciting news for all Americans, but encouraged Americans to avoid letting down their guard.
This struggle is far from over, I want to become transparent, he said. I encourage all Americans to continuously wash their face, remain socially distant and wear masks. As I have already said, it is still possible that things could get worse as new variants expand and the latest improvements may go backwards.
A FDA consultation panel approved the vaccine overwhelmingly on Friday to pave the way for the approval of the department.
This is just a small percentage of the more than eight million people in the United States who have been given the CDC vaccine of Johnson & Johnson so far. In these, thirteen were women from 18 to 49 years of age and two were women from 50 and older years of age. For women aged 18 to 49 years, this means that they seem to be at 7 per million risk of forming certain blood clots and 0.9 per million for women aged 50. According to the speakers at the ACIP, there are another 10 cases still under investigation, including males.
Three of these patients have been killed and seven remain in hospital. In the case of people who acquired TTS there are no strong trends other than younger and more feminine risk factors; 7 were obese; 2 had hypothyroidism; 2 were using oral contraception, and 2 had elevated blood pressure.
The group addressed a range of options to perform the vaccination of Johnson & Johnson in the United States, including the suggestion that the vaccine be administered among both the 18 years and older and that an age limit be determined because TTS cases appear more frequent among younger populations.
Adenoviral-based vaccine close to AstraZeneca and Oxford University is the Johnson & Johnson vaccine. Live science has also confirmed that the vaccine AstraZeneca has led to TTS cases and has been paused through several countries while being examined; most countries have reinstated the AstraZeneca shot but with different age limits and directives.
No TTS records have occurred from the more than 214 million doses of mRNA vaccines delivered by Moderna and Pfizer in the U.S.
